Seed Therapeutics applies a proprietary platform to create molecular glue degraders that induce targeted protein degradation in cancer and other diseases. Its lead program, ST-01156, is a first-in-class degrader aimed at RBM39 and has just received FDA clearance of its Investigational New Drug application. The company intends to initiate first-in-human clinical trials for ST-01156 in the first quarter of 2026, marking its transition to a clinical-stage enterprise. Beyond the newly announced financing, Seed has accumulated nearly $60 million through equity, upfront, and milestone payments stemming from strategic partnerships with Eli Lilly and Eisai. These resources, combined with the latest capital infusion, are expected to support advancement of ST-01156 and expansion of a broader pipeline of molecular glue degraders. Seed Therapeutics’ management highlights the combined strength of venture financing and collaboration payments as key to sustaining its clinical and discovery programs.

Total raised

$54M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2025